Empower Clinics Continues to Advance Development of Psilocybin and Psychedelics Division to Address Significant Mental Health Issues

Shares :

0
(0)

Empower is utilizing clinics, physicians, technology and direct access to 165,000 patients to launch dedicated division and resources for psilocybin research.

VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / EMPOWER CLINICS INC. (CSE: CBDT)(OTC: EPWCF)(Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated and growth-oriented life sciences company is pleased to announce, it is has created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder (PTSD) and addiction.

The Company is leveraging its assets that include the existing clinic network, the developing franchise brand, tele-medicine, access to its 165,000 patients and large physician team, to make advancements in psilocybin research and psychedelics therapy in general.


This image has an empty alt attribute; its file name is revivelogo2.2.png

REVIVE THERAPEUTICS | RVV UP 32% YESTERDAY| LOOK WHY


“Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic.” said Steven McAuley, Chairman & CEO of Empower. “Clinical trials continue to show that psilocybin therapies may provide tremendous help with these conditions, that we see every day in our clinics. As a Company, we must endeavour to utilize our assets and capabilities to positively impact patients’ lives.”

The mental health crisis could cost the world $16 trillion by 2030 according to Future Market Insights and further, the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and it is a major contributor to the overall global burden of disease.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

LAST ALERT MADE MORE THAN 170% TO DATE !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.


Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :